Committed to Our Vision of Curing Patients with Infectious Diseases and Cancers

"It is an exciting time to join the Enochian Bioscience Board, and I am looking forward to making an active contribution to bring their innovative science to many patients."

-Mr. Debruyne, ex-President of Global Vaccines GSK and independent director of Enochian Biosciences

Company

Based in Los Angeles, Enochian BioSciences Inc. is a gene-modified cell therapy company with a clear mission: develop definitive cures and provide effective prevention for infectious diseases and cancer. After the acquisition of Enochian Biopharma early 2018, Enochian Biosciences Inc. (former DanDrit Biotech USA Inc.) is poised to change the course of gene-modified cell therapy treatments through expert insights and dedicated efforts.

Our objectives:



HIV preventative vaccine and cures

Cellular immune-oncology products for the prevention of relapse of metastatic colon cancer after resection and chemotherapy

Allogeneic genetically-modified dendritic cell platform for treatment of cancer

Management Team

Our core management team combines the relevant HIV/AIDS and oncology development experience: Pharmaceutical industry, biotech and academia. We opt for outsourcing manufacturing and regulatory (based on past experience of other biotech companies developing advanced therapies).

Dr. Eric Leire

Chief Executive officer

Dr. Eric Leire has served as the Chief Executive Officer and a director of DanDrit Denmark since June 2017 and previously from April 2011 to March 2017. Dr. Leire also served for two years as Chief Executive Officer and director of DKTI A/S, a listed Danish investment company from September 2012. Prior to these roles Dr. Leire was a partner at BioFund Venture Capital, a Finnish biotech venture fund, from August 2006 through September 2010 and a partner at Medwell Capital Corp., a Canadian venture fund, from April 2010 through May 2011. Dr. Leire has worked globally for many international pharmaceutical organizations, including Schering-Plough, Pfizer, Inc., Boots Pharmaceuticals Company PLC, Harvard AIDS Institute and BioStrategies Group. Dr. Leire also served as the CEO of U.S. biotech companies APT Therapeutics and Paringenix and currently serves on the board of directors of Novicol Canada. Dr. Leire received his medical degree from the University of Medicine of Grenoble in 1980 and his MBA from ISA-HEC and the Kellogg School of Management at Northwestern University in 1991.

Dr. Serhat Gümrükcü

Inventor

Has over a decade of research and practice in the field of personalized medicine, focusing on regenerative treatment modalities using stem cell technologies, biological treatments, cancer immunotherapy, and nanoparticle delivery systems.

Dr. Gumrukcu's pioneering practice has led to multiple breakthrough achievements in the field of regenerative medicine for patients suffering from traumatic or chronic degenerative diseases including cerebral palsy, stroke, brain and spinal injuries causing paralysis, degenerative eye (optic nerve or retina) diseases resulting with blindness, as well as autoimmune and chronic degenerative diseases like MS, Myasthenia Gravis, Alzheimer's disease, Parkinson's disease and many others alike.

Mr. Robert Wolfe

Chief Financial Officer

Robert Wolfe has served as the Chief Financial Officer and Director from January 2014 to April 2015 and has served as Chief Financial Officer since July 2017. Concurrently, Mr. Wolfe is the Chairman and CEO for Advanced Oxygen Technologies Inc. since 1997, the President and CEO of Crossfield, Inc. since 1989. From 1992-1993 he was Vice President and partner for CFI, NY Ltd., a subsidiary of Corporate Financial Investments, PLC, London.

Dr. Wenshi Wang

SVP Operations

Dr. Wang has been actively overseeing, working and completing Investigation New Drug (IND) filing with FDA on stem cell and T cell therapy demonstrating her leadership in drug discovery and development. Dr. Wang completed her clinical medicine and her Immunology PhD training in China and at Heidelberg University in Germany. In the United States, Dr. Wang advanced her career in translational immune-oncology at the University of Southern California and Moffitt Cancer Center in Florida with achievements in patent issuance and publications in the industry's top peer-reviewed journals.

Mr. Tung Nguyen

Senior Molecular Biologist

Devoting more than a quarter of a century on research with focus on signal transduction and molecular basic of cancer and infection, Tung is eager to transform his passion for Science into cures for diseases, to fulfill his life-long wish on helping people and saving lives.

He conducted research at the Molecular Oncology Department at John Wayne Cancer Institute, the Molecular Host Defense Laboratory at UCLA and the Molecular Immunology at Beckman Research Institute at City of Hope Medical Center. And "this is exactly where I want to be today ...", he stated upon joining Enochian Biosciences team.

Board of Directors

Mr. Rene Sindlev

Chairman

Mr. Sindlev has been successfully self employed since 1985 from an age of 23. He has been an investor and entrepreneur since 1997 through his investment holding company, RS Group ApS. Since 2012, his holding companies have included RS Group ApS, RS Arving ApS, RS Family ApS and RS Newton ApS. In January of 2014, Mr. Sindlev established Dr. Smood ApS in Denmark, and Dr. Smood Group, Inc. in the United States, a chain of natural health-conscious restaurants, and since January of 2014 he has served as its chairman. Mr. Sindlev has previously founded, owned and sold more than 28 companies in the Jewelry, Aviation, Charter and Real Estate Business, such as World og Watches A/S, Pandora A/S, RS Aviation ApS, Gråbrødrestrœde ApS among others. In 2002 Mr. Sindlev co-founded Pandora Jewelry America ApS, and served as President, board member and advisor to the board until its IPO on Nasdaq Copenhagen in 2010. We believe Mr. Sindlev's experience as an entrepreneur in successfully building start-up companies from the ground up qualifies him to serve as a director.

Dr. Mark Dybul

Vice Chairman

Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality since June of 2017. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O'Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President's Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University. Dr. Dybul is a member of the national academy of medicine. We believe Dr. Dybul's extensive high-level clinical and institutional experience in the field of HIV/AIDS qualifies him to serve as a director.

Ms. Evelyn D'An

Independent Director

Ms. D'An is an experienced independent director and experienced chair of audit, compensation and nominating/governance committees with various public companies. She has also worked as a CFO, as a former Big 4 Audit Partner and has been a Hispanic business leader in the community for many years. MS. D'An spent 18 years with Ernst & Young where she served clients in retail, consumer products, technology, financial services, media and other sectors. As President of D'An Financial Services, she has continued to provide a variety of financial and operational leadership support to her clients since 2004. Ms. D'An has a diverse background which offers a valuable combination of private equity ownership experience, along with public company corporate governance and reporting. Throughout her career, she has taken on financial and operational leadership roles, including Senior Vice President of Finance and Accounting for Brightstar Corporation, a $5B global distributor and service provider for the wireless industry. Ms. D'An also led and participated in several successful initial public offerings, debt restructuring, multiple mergers and acquisitions and transformation of a best in class accounting and financial reporting infrastructure. Ms. D'An has been serving on corporate boards since 2005. Since 2016, she has also served on the board of Summer Infant, a NASDAQ manufacturer of infant and juvenile products, with distribution into major retailers such as Target, Walmart and Amazon. She graduated with a Masters of Accounting from Florida International University and a Bachelor of Science from the State University of Albany. We believe Ms. D'An's significant corporate governance, financial and accounting expertise qualifies her to serve as a director.

Mr. James Sapirstein

Independent Director

Mr. Sapirstein joined the Board of Directors of the Registrant having served over thirty years in the pharmaceutical industry. He has been part of almost two dozen product launches and specifically either led or been a key member of several HIV product launches into a new class of therapeutics at that time. Most recently from March 18, 2014 until October 3, 2018, he served as the CEO of ContraVir Pharmaceuticals, Inc., which is a company specializing in the Hepatitis B space. After beginning his career in 1984 with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the US and abroad. He held a number of positions at Hoffmann-LaRoche, before moving to Bristol Myers Squibb in 1996 the Director of International Marketing in the Infectious Disease group. While at BMS, he worked on several important HIV/AIDS projects including Secure the Future. Mr. Sapirstein started his career in smaller biotech companies when he later joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir) In 2002, he accepted the position of Executive Vice President Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc., prior to joining Contravir. Mr. Sapirstein holds board positions with RespireRx Pharmaceuticals (RSPI) and Leading Biosciences. He is also the Chairman of BioNJ and a Board Director for BIO, where he sits on both the Health Section Governing and Emerging Companies Section Governing Boards. Mr. Sapirstein received his MBA from Fairleigh Dickinson University and B.Pharm. from Rutgers University. We believe Mr. Sapirstein's extensive experience as a biotechnology executive and as a board member in biopharma industry and industry associations qualifies him to serve as a director.

Mr. Luc Debruyne

Independent Director

Luc Debruyne joined the board of Enochian Biosciences October 2018 as an Independent Director Previously he worked for GSK as President Global Vaccines and was a member of GSK's Corporate Executive Team till Sept 2018. Luc joined GSK in 1991, after 4 years working at BMS. He worked as a commercial strategy director in R&D , before leading the European Commercial Centre of Excellence. In 2006, Luc became GM in GSK Netherlands and then in 2010 SVP & GM Italy . In 2012, he was appointed SVP Pharma Europe and became GSK's President Global Vaccines in 2013 . Luc will be leaving GSK at the end of 2018. He holds a Master's Degree in Physical Education from the University of Leuven.

Mr. Carl Sandler

Member

Mr. Sandler is a serial tech and healthcare CEO who has built numerous consumer-facing technology and healthcare brands. He was the CEO of Enochian BioPharma, Inc. prior to its acquisition by the Registrant and has been the Manager of Weird Science, LLC since March of 2017. Mr. Sandler is a widely respected thought leader, journalist and speaker on issues related to public health, HIV / AIDS, sex and sexuality. He has spoken extensively at AIDS / HIV conferences worldwide about innovative uses of technology in public health. In addition to his journalism and speaking engagements and prior to his position with Weird Science, Mr. Sandler was the Manager of DH Services, LLC, an application developer, and the CEO of True Sons Grooming, a subscription service. We believe Mr. Sandler's significant experience in the HIV/AIDS community and as an entrepreneur qualifies him to serve as a director.

Mr. Henrik Grønfeldt-Sørensen

Member

Mr. Gronfeldt-Sorensen is has been the Chief Executive Officer of RS Group ApS, RS Arving ApS, RS Family ApS and RS Newton ApS since October of 2012, and he has served as a director of DrSmood Group, Inc. since January of 2014. Mr. Gronfeldt-Sorensen has over 10 years' experience from different CEO & management positions; Danske Bank in Denmark, the Danish Bank Nykredit in France. RS Group of Companies, a family office in Denmark with global investments within real estate, charter business, food & beverage, private hospitals and biosciences. Mr. Gronfeldt-Sorensen holds a eMBA from University of Monaco (2011).

Dr. Eric Leire

CEO & Board Observer

Dr. Eric Leire has served as the Chief Executive Officer and a director of DanDrit Denmark since June 2017 and previously from April 2011 to March 2017. Dr. Leire also served for two years as Chief Executive Officer and director of DKTI A/S, a listed Danish investment company from September 2012. Prior to these roles Dr. Leire was a partner at BioFund Venture Capital, a Finnish biotech venture fund, from August 2006 through September 2010 and a partner at Medwell Capital Corp., a Canadian venture fund, from April 2010 through May 2011. Dr. Leire has worked globally for many international pharmaceutical organizations, including Schering-Plough, Pfizer, Inc., Boots Pharmaceuticals Company PLC, Harvard AIDS Institute and BioStrategies Group. Dr. Leire also served as the CEO of U.S. biotech companies APT Therapeutics and Paringenix and currently serves on the board of directors of Novicol Canada. Dr. Leire received his medical degree from the University of Medicine of Grenoble in 1980 and his MBA from ISA-HEC and the Kellogg School of Management at Northwestern University in 1991.

Scientific Advisory Board (SAB) with HIV/AIDS expertise

Dr. Mark Dybul

Chairman

Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality since June of 2017. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O'Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President's Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University. Dr. Dybul is a member of the national academy of medicine. We believe Dr. Dybul's extensive high-level clinical and institutional experience in the field of HIV/AIDS qualifies him to serve as a director.

Dr. Steven G. Deeks

Member

Dr. Deeks is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the "reservoir") and health during antiretroviral therapy.

Dr. HP Kiem

Member

Dr. Kiem's research has focused on stem cell and transplantation biology, cell and gene therapy and the development and use of novel gene editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer. Dr. Kiem is the Sponsor of 4 clinical gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and he is the Principal Investigator or Co-Principal Investigator of many R01 or P01 grants including a Martin Delaney Consortium grant to study HIV cure strategies (defeat HIV). Dr. Kiem has also served on the NIH Recombinant DNA Advisory Committee for the last 5 years and as Chair this past year. He is currently the Chair of the Stem Cell Committees for both the American Society for Gene and Cell Therapy and the American Society of Hematology. Dr. Kiem has extensive experience training students and postdoctoral fellows and has mentored more than 50 trainees in his lab over the past 20 years. Many of his trainees now hold tenured faculty positions in the US and in Germany.

Dr. W. David Hardy

Member

Dr. Hardy currently serves as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator and HIV/primary care provider at Whitman-Walker Health in Washington, D.C. and also holds an Adjunct Professor of Medicine appointment at Johns Hopkins University School of Medicine in Baltimore. Dr. Hardy currently serves as Chair-elect of the Board of Directors of HIV Medicine Association (HIVMA), Chair of the Education Committee of the American Academy of HIV Medicine (AAHIVM) and Editor-in-Chief of AAHIVM's comprehensive textbook Fundamentals of HIV Medicine for the HIV Specialist, published in 2012 and 2016. He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA, and just prior to joining Whitman-Walker, he was Chief Medical Officer for Calimmune, a biotechnology company investigating gene-modified CD4+ T cells and hematopoietic stem cells as a potential therapy for HIV infection.